Fidson Healthcare Stock Rallies 37% in Early January Trading
Fidson Healthcare Plc has commenced the new year with a significant rally on the Nigerian Exchange (NGX), with its share price appreciating by over 37% month-to-date. As of the premarket session on January 9, 2026, the stock soared to N69, approaching the N70 threshold. This surge follows an extraordinary performance in 2025, where the stock recorded a 231.5% gain, with investors likely responding to the company’s robust financial fundamentals and strategic initiatives.
Strong Financial Performance Drives Investor Confidence
The bullish sentiment is anchored in the company’s recently reported earnings. For the third quarter of 2025, Fidson posted a pre-tax profit of N2.9 billion, a marginal increase from the N2.87 billion achieved in Q3 2024. Over a longer horizon, the nine-month period ended September 30, 2025, saw pre-tax profit climb to N11.9 billion, representing a 131.74% year-on-year increase. This growth was driven by a 35.4% rise in Q3 revenue, which reached N30.4 billion compared to N22.47 billion in the corresponding quarter of the prior year. While costs, including sales and administrative expenses, also rose, the company maintained profitability through increased operational efficiency.
Strategic Expansion and Capital Raise
Further bolstering market optimism is Fidson’s strategic direction. In December 2025, the company formally launched a N21 billion Rights Issue, offering 600 million new ordinary shares at N35 each. The capital raise, structured as one new share for every four held, is intended to fund manufacturing capacity expansion, product development, and growth across Africa. This initiative follows a technical assistance agreement with Japan’s Ohara Pharmaceutical Co. Ltd., a partnership aimed at enhancing local production and reducing Nigeria’s reliance on imported medicines. These developments appear to have positioned the company favorably for future growth, prompting investors to take early positions in January 2026.
As market dynamics continue to evolve, with news ranging from policy directions, such as when Tinubu condoles Abba, to sector-specific events like Overland Airways resumes certain routes, the performance of fundamentally sound companies like Fidson captures significant attention. The company’s journey reflects a broader narrative of corporate growth within the Nigerian market, drawing parallels to developments in other sectors, whether in education, as seen when Futa withdraws certificates, or in regional initiatives championed by figures like the Ebonyi First Lady. The strategic focus on continental expansion also hints at ambitions that could see the company looking toward 5 countries that offer key growth markets for pharmaceutical products in the future.
